Guidant to distribute Thoratec's Vectra:
This article was originally published in Clinica
Executive Summary
Guidant is to gain exclusive worldwide distribution rights to Thoratec's Vectra vascular access graft for a total of $3.5 million. Guidant has also issued Thoratec a four-year, unsecured credit line of $10 million. The product, which is approved for sale in Europe, provides access to the blood stream for dialysis patients. Thoratec has begun clinical trials for the product in the US. Guidant says Vectra complements its own products for the treatment of abdominal aortic aneurysms.